Clinical and Translational Oncology

, Volume 20, Issue 11, pp 1373–1384 | Cite as

Cutaneous toxicities of new treatments for melanoma

  • A. BoadaEmail author
  • C. Carrera
  • S. Segura
  • H. Collgros
  • P. Pasquali
  • D. Bodet
  • S. Puig
  • J. Malvehy
Review Article


New drugs against advanced melanoma have emerged during last decade. Target therapy and immunotherapy have changed the management of patients with metastatic disease. Along with its generalized use, drug toxicities have appeared and the skin is the target organ of a significant part of them. This revision summarizes the most common side effects and consensus management to improve the compliance of therapies and patients’ quality of life. Among the BRAF inhibitors, main cutaneous side effects are photosensitivity, plantar hyperkeratosis, and the appearance of verrucal keratosis or squamous cell carcinoma. Special attention must be paid to the development of new primary melanomas or changes on nevi during BRAF inhibitor therapy. The most common cutaneous side effects of immunotherapy are rash, pruritus, and vitiligo. It remains controversial the possible role of these toxicities as markers of response to therapy.


Melanoma Target therapy Immunotherapy Toxicity Nivolumab Pembrolizumab 


Compliance with ethical standards

Disclosure of potential conflicts of interest

Dr. Aram Boada has received speaker honorarium from Roche, Novartis, and BMS. Dr. Susana Puig has been consultant of Amgen, ISDIN, La Roche Posay, Leo Pharma, Almirall, Piere Fabre, BMS, and has received research grants from Leo Pharma, Almirall, and Novartis. Dr. Josep Malvehy has been consultant of Amgen, Novartis, BMS, Glaxo, Piere Fabre, Merk, MSD, Sanofi, Sunpharma, Incyte, Almirall, Leo Pharma, ISDIN, and has received research grants from Amgen, Novartis, Roche, BMS, Glaxo, Pierre Fabre, Merk, MSD, Sanofi, Sunpharma, Incyte, Almirall, and Leo Pharma. The remaining authors have no conflict of interest to declare.

Ethical standards

The manuscript does not contain clinical studies or patient data.

Informed consent

Informed consent was obtained from all individual for whom identifying pictures are included in this article.


  1. 1.
    Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–14.CrossRefPubMedGoogle Scholar
  2. 2.
    Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–76.CrossRefPubMedGoogle Scholar
  3. 3.
    Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26.CrossRefPubMedGoogle Scholar
  4. 4.
    Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30.CrossRefPubMedGoogle Scholar
  5. 5.
    Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32.CrossRefPubMedGoogle Scholar
  6. 6.
    Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813–23.CrossRefPubMedGoogle Scholar
  7. 7.
    Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35.CrossRefPubMedGoogle Scholar
  8. 8.
    Boada A. Toxicidad cutánea de los inhibidores del BRAF y del MEK. Piel. 2015;30(5):309–15.CrossRefGoogle Scholar
  9. 9.
    Hwang SJE, Anforth R, Carlos G, Fernandez-Peñas P. Cutaneous adverse events of new anti-melanoma therapies: classification and management. Actas Dermosifiliogr. 2017;108(1):6–16.CrossRefPubMedGoogle Scholar
  10. 10.
    Anforth R, Fernandez-Peñas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 2013;14(1):e11–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–14.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med. 2012;366(5):480–1.CrossRefPubMedGoogle Scholar
  13. 13.
    Brugière C, Stefan A, Morice C, Cornet E, Moreau A, Allouche S, et al. Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease. Br J Dermatol. 2014;171(6):1529–32.CrossRefPubMedGoogle Scholar
  14. 14.
    Gelot P, Dutartre H, Khammari A, Boisrobert A, Schmitt C, Deybach J-C, et al. Vemurafenib: an unusual UVA-induced photosensitivity. Exp Dermatol. 2013;22(4):297–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Gabeff R, Dutartre H, Khammari A, Boisrobert A, Nguyen J-M, Quereux G, et al. Phototoxicity of B-RAF inhibitors: exclusively due to UVA radiation and rapidly regressive. Eur J Dermatol. 2015;25(5):452–6.PubMedGoogle Scholar
  16. 16.
    Satzger I, Degen A, Asper H, Kapp A, Hauschild A, Gutzmer R. Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol. 2013;31(13):e220–2.CrossRefPubMedGoogle Scholar
  17. 17.
    Hecht M, Zimmer L, Loquai C, Weishaupt C, Gutzmer R, Schuster B, et al. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Ann Oncol. 2015;26(6):1238–44.CrossRefPubMedGoogle Scholar
  18. 18.
    Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809–19.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol. 2012;67(6):1265–72.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S, et al. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol. 2015;151(10):1103–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Specchio F, Argenziano G, Tiodorovic-Zivkovic D, Moscarella E, Lallas A, Zalaudek I, et al. Dermoscopic clues to diagnose acantholytic dyskeratosis. Dermatol Pract Concept. 2015;5(1):59–60.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Park JJ, Hawryluk EB, Tahan SR, Flaherty K, Kim CC. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma. JAMA Dermatol. 2014;150(3):307–11.CrossRefPubMedGoogle Scholar
  23. 23.
    Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24(6):1691–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Anforth RM, Blumetti TC, Kefford RF, Sharma R, Scolyer RA, Kossard S, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol. 2012;167(5):1153–60.CrossRefPubMedGoogle Scholar
  25. 25.
    Piraccini BM, Patrizi A, Fanti PA, Starace M, Bruni F, Melotti B, et al. RASopathic alopecia: hair changes associated with vemurafenib therapy. J Am Acad Dermatol. 2015;72(4):738–41.CrossRefPubMedGoogle Scholar
  26. 26.
    Choy B, Chou S, Anforth R, Fernández-Peñas P. Panniculitis in patients treated with BRAF inhibitors: a case series. Am J Dermatopathol. 2014;36(6):493–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Zimmer L, Livingstone E, Hillen U, Dömkes S, Becker A, Schadendorf D. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol. 2012;148(3):357–61.CrossRefPubMedGoogle Scholar
  28. 28.
    Monfort J-B, Pagès C, Schneider P, Neyns B, Comte C, Bagot M, et al. Vemurafenib-induced neutrophilic panniculitis. Melanoma Res. 2012;22(5):399–401.CrossRefPubMedGoogle Scholar
  29. 29.
    Mössner R, Zimmer L, Berking C, Hoeller C, Loquai C, Richtig E, et al. Erythema nodosum-like lesions during BRAF inhibitor therapy: report on 16 new cases and review of the literature. J Eur Acad Dermatol Venereol. 2015;29(9):1797–806.CrossRefPubMedGoogle Scholar
  30. 30.
    Yorio JT, Mays SR, Ciurea AM, Cohen PR, Wang W-L, Hwu W-J, et al. Case of vemurafenib-induced sweet’s syndrome. J Dermatol. 2014;41(9):817–20.CrossRefPubMedGoogle Scholar
  31. 31.
    Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res. 2012;18(2):555–67.CrossRefPubMedGoogle Scholar
  32. 32.
    Sinha R, Lecamwasam K, Purshouse K, Reed J, Middleton MR, Fearfield L. Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma. Br J Dermatol. 2014;170(4):997–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Wenk KS, Pichard DC, Nasabzadeh T, Jang S, Venna SS. Vemurafenib-induced DRESS. JAMA Dermatol. 2013;149(10):1242–3.CrossRefPubMedGoogle Scholar
  34. 34.
    Adam A, Thomas L, Bories N, Zaharia D, Balme B, Freymond N, et al. Sarcoidosis associated with vemurafenib. Br J Dermatol. 2013;169(1):206–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Ma L, Dominguez AR, Collins GR, Kia KF, Cockerell CJ. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib. Arch Dermatol. 2012;148(12):1428–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15(4):436–44.CrossRefPubMedGoogle Scholar
  38. 38.
    Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65.CrossRefPubMedGoogle Scholar
  39. 39.
    Belum VR, Rosen AC, Jaimes N, Dranitsaris G, Pulitzer MP, Busam KJ, et al. Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients. Cancer. 2015;121(1):60–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Anforth R, Carlos G, Clements A, Kefford R, Fernandez-Peñas P. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. Br J Dermatol. 2015;172(1):239–43.CrossRefPubMedGoogle Scholar
  41. 41.
    Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol. 2012;30(3):316–21.CrossRefPubMedGoogle Scholar
  42. 42.
    Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207–15.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Weeraratna AT. RAF around the edges—the paradox of BRAF inhibitors. N Engl J Med. 2012;366(3):271–3.CrossRefPubMedGoogle Scholar
  44. 44.
    Wu JH, Cohen DN, Rady PL, Tyring SK. BRAF inhibitor-associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for a viral involvement, and perspectives on clinical management. Br J Dermatol. 2017;177(4):914–23.CrossRefPubMedGoogle Scholar
  45. 45.
    Lallas A, Pyne J, Kyrgidis A, Andreani S, Argenziano G, Cavaller A, et al. The clinical and dermoscopic features of invasive cutaneous squamous cell carcinoma depend on the histopathological grade of differentiation. Br J Dermatol. 2015;172(5):1308–15.CrossRefPubMedGoogle Scholar
  46. 46.
    Stratigos A, Garbe C, Lebbe C, Malvehy J, del Marmol V, Pehamberger H, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51(14):1989–2007.CrossRefPubMedGoogle Scholar
  47. 47.
    Dirschka T, Gupta G, Micali G, Stockfleth E, Basset-Séguin N, Del Marmol V, et al. Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. J Dermatolog Treat. 2017;28(5):431–42.CrossRefPubMedGoogle Scholar
  48. 48.
    Anforth R, Blumetti TC, Clements A, Kefford R, Long GV, Fernandez-Peñas P. Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. Br J Dermatol. 2013;169(6):1310–3.CrossRefPubMedGoogle Scholar
  49. 49.
    Sachse MM, Wagner G. Clearance of BRAF inhibitor-associated keratoacanthomas by systemic retinoids. Br J Dermatol. 2014;170(2):475–7.CrossRefPubMedGoogle Scholar
  50. 50.
    Anforth R, Fernandez-Penas P. BRAF inhibitor induced verrucal keratosis. Am J Dermatopathol. 2014;36(2):192.CrossRefPubMedGoogle Scholar
  51. 51.
    Anforth R, Tembe V, Blumetti T, Fernandez-Peñas P. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. Pigment Cell Melanoma Res. 2012;25(5):569–72.CrossRefPubMedGoogle Scholar
  52. 52.
    Kong HH, Sibaud V, Chanco Turner ML, Fojo T, Hornyak TJ, Chevreau C. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol. 2008;144(6):820–2.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–32.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;365(15):1448–9.CrossRefPubMedGoogle Scholar
  55. 55.
    Gerami P, Sorrell J, Martini M. Dermatoscopic evolution of dysplastic nevi showing high-grade dysplasia in a metastatic melanoma patient on vemurafenib. J Am Acad Dermatol. 2012;67(6):e275–6.CrossRefPubMedGoogle Scholar
  56. 56.
    Haenssle HA, Kraus SL, Brehmer F, Kretschmer L, Völker B, Asper H, et al. Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy. Arch Dermatol. 2012;148(10):1183–5.CrossRefPubMedGoogle Scholar
  57. 57.
    Perier-Muzet M, Thomas L, Poulalhon N, Debarbieux S, Bringuier P-P, Duru G, et al. Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy. J Invest Dermatol. 2014;134(5):1351–8.CrossRefPubMedGoogle Scholar
  58. 58.
    Carrera C, Puig-Butillè JA, Tell-Marti G, García A, Badenas C, Alós L, et al. Multiple BRAF wild-type melanomas during dabrafenib treatment for metastatic BRAF-mutant melanoma. JAMA Dermatol. 2015;151(5):544–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF Inhibition. J Clin Oncol. 2012;30(19):2375–83.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Mudaliar K, Tetzlaff MT, Duvic M, Ciurea A, Hymes S, Milton DR, et al. BRAF inhibitor therapy—associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. Hum Pathol. 2016;50:79–89.CrossRefPubMedGoogle Scholar
  61. 61.
    Dalle S, Poulalhon N, Debarbieux S, Zaharia D, Mihm MC, Lacouture ME, et al. Tracking of second primary melanomas in vemurafenib-treated patients. JAMA Dermatol. 2013;149(4):488–90.CrossRefPubMedGoogle Scholar
  62. 62.
    Loewe R, Kittler H, Fischer G, Faé I, Wolff K, Petzelbauer P. BRAF kinase gene V599E mutation in growing melanocytic lesions. J Invest Dermatol. 2004;123:733–6.CrossRefPubMedGoogle Scholar
  63. 63.
    Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436(7051):720–4.CrossRefPubMedGoogle Scholar
  64. 64.
    Kumar R, Angelini S, Snellman E, Kemminki K. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol. 2004;122:342–8.CrossRefPubMedGoogle Scholar
  65. 65.
    Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KSM. Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol. 2013;10(7):390–9.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, et al. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014;71(6):1102–9 (e1).CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Erfan G, Puig S, Carrera C, Arance A, Gaba L, Victoria I, et al. Development of cutaneous toxicities during selective anti-BRAF therapies: preventive role of combination with MEK inhibitors. Acta Derm Venereol. 2017;97(2):258–60.CrossRefPubMedGoogle Scholar
  68. 68.
    Dréno B, Ribas A, Larkin J, Ascierto PA, Hauschild A, Thomas L, et al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol. 2017;28(5):1137–44.CrossRefPubMedGoogle Scholar
  69. 69.
    Anforth R, Liu M, Nguyen B, Uribe P, Kefford R, Clements A, et al. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol. 2014;55(4):250–4.CrossRefPubMedGoogle Scholar
  70. 70.
    Abdel-Rahman O, Elhalawani H, Ahmed H. Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data. Clin Transl Oncol. 2016;18(8):848–58.CrossRefPubMedGoogle Scholar
  71. 71.
    Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691–7.CrossRefPubMedGoogle Scholar
  72. 72.
    Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15(17):5591–8.CrossRefPubMedGoogle Scholar
  73. 73.
    Vennepureddy A, Thumallapally N, Motilal V. Novel drugs and combination therapies for the treatment of metastatic melanoma. J Clin Med Res. 2016;8(2):63–75.CrossRefPubMedGoogle Scholar
  74. 74.
    Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015;72(2):221–36.CrossRefPubMedGoogle Scholar
  75. 75.
    Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151(11):1206–12.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–17.CrossRefPubMedGoogle Scholar
  78. 78.
    Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–30.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Hwang SJE, Carlos G, Wakade D, Byth K, Kong BY, Chou S, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016;74(3):455–61 (e1).CrossRefPubMedGoogle Scholar
  80. 80.
    Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2013;69(3):e121–8.CrossRefPubMedGoogle Scholar
  81. 81.
    Joseph RW, Cappel M, Goedjen B, Gordon M, Kirsch B, Gilstrap C, et al. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res. 2015;3(1):18–22.CrossRefPubMedGoogle Scholar
  82. 82.
    Ensslin CJ, Rosen AC, Wu S, Lacouture ME. Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol. 2013;69(5):708–20.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Sullivan RJ, Flaherty KT. Pembrolizumab for treatment of patients with advanced or unresectable melanoma. Clin Cancer Res. 2015;21(13):2892–7.CrossRefPubMedGoogle Scholar
  84. 84.
    Ito J, Fujimoto D, Nakamura A, Nagano T, Uehara K, Imai Y, et al. Aprepitant for refractory nivolumab-induced pruritus. Lung Cancer. 2017;109:58–61.CrossRefPubMedGoogle Scholar
  85. 85.
    Larsabal M, Marti A, Jacquemin C, Rambert J, Thiolat D, Dousset L, et al. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death—1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol. 2017;76(5):863–70.CrossRefPubMedGoogle Scholar
  86. 86.
    Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45–51.CrossRefPubMedGoogle Scholar
  87. 87.
    Weber JS, O’Day S, Urba W, Powderly J, Nichol G, Yellin M, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26(36):5950–6.CrossRefPubMedGoogle Scholar
  88. 88.
    Rivera N, Boada A, Bielsa MI, Fernández-Figueras MT, Carcereny E, Moran MT, et al. Hair repigmentation during immunotherapy treatment with an anti-programmed cell death 1 and anti-programmed cell death ligand 1 agent for lung cancer. JAMA Dermatol. 2017;153(11):1162–5.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Hwang SJE, Carlos G, Chou S, Wakade D, Carlino MS, Fernandez-Penas P. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Res. 2016;26(4):413–6.CrossRefPubMedGoogle Scholar
  90. 90.
    Le Naour S, Peuvrel L, Saint-Jean M, Dreno B, Quereux G. Three new cases of bullous pemphigoid during anti-PD-1 antibody therapy. J Eur Acad Dermatol Venereol. 2018;32(3):e104–6.CrossRefPubMedGoogle Scholar
  91. 91.
    Ohtsuka M, Miura T, Mori T, Ishikawa M, Yamamoto T. Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma. JAMA Dermatol. 2015;151(7):797–9.CrossRefPubMedGoogle Scholar
  92. 92.
    Bonigen J, Raynaud-Donzel C, Hureaux J, Kramkimel N, Blom A, Jeudy G, et al. Anti-PD1-induced psoriasis. A study of 21 patients. J Eur Acad Dermatol Venereol. 2017;31(5):e254–7.CrossRefPubMedGoogle Scholar
  93. 93.
    Sahuquillo-Torralba A, Ballester-Sánchez R, Pujol-Marco C, Botella-Estrada R. Pembrolizumab: a new drug that can induce exacerbations of psoriasis. Actas Dermosifiliogr. 2016;107(3):264–6.CrossRefPubMedGoogle Scholar
  94. 94.
    Kato Y, Otsuka A, Miyachi Y, Kabashima K. Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. J Eur Acad Dermatol Venereol. 2016;30(10):e89–91.CrossRefPubMedGoogle Scholar
  95. 95.
    Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJ, Hobo W, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother. 2012;35(2):169–78.CrossRefPubMedGoogle Scholar
  96. 96.
    Freites-Martinez A, Kwong BY, Rieger KE, Coit DG, Colevas AD, Lacouture ME. Eruptive keratoacanthomas associated with pembrolizumab therapy. JAMA Dermatol. 2017;153(7):694.CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Pintova S, Sidhu H, Friedlander PA, Holcombe RF. Sweet’s syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res. 2013;23(6):498–501.CrossRefPubMedGoogle Scholar
  98. 98.
    Munoz J, Guillot B, Girard C, Dereure O, Du-Thanh A. First report of ipilimumab-induced grover disease. Br J Dermatol. 2014;171(5):1236–7.CrossRefPubMedGoogle Scholar
  99. 99.
    Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, Korivi BR, Landon GA, Nagarajan P, et al. Erythema nodosum-like panniculitis mimicking disease recurrence: a novel toxicity from immune checkpoint blockade therapy. Report of two patients. J Cutan Pathol. 2017;44(12):1080–6.CrossRefPubMedGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2018

Authors and Affiliations

  1. 1.Dermatology Department, Hospital Universitari Germans Trias i PujolUniversitat Autònoma de BarcelonaBarcelonaSpain
  2. 2.Melanoma Unit, Dermatology Department, Hospital Clinic, Institut d’investigacions biomèdiques August Pi i Sunyer (IDIBAPS), CIBERERUniversitat de BarcelonaBarcelonaSpain
  3. 3.Dermatology Department, Hospital del Mar, Parc de Salut MarFundació Institut Mar d’Investigacions MèdiquesBarcelonaSpain
  4. 4.Sydney Melanoma Diagnostic CentreRoyal Prince Alfred HospitalSidneyAustralia
  5. 5.Dermatology Department, Pius Hospital VallsInstitut d’Investigació Sanitària Pere Virgili VallsTarragonaSpain
  6. 6.Dermatology DepartmentHospital Universitari Vall d’Hebron, VHIRBarcelonaSpain

Personalised recommendations